News
ABEO
7.53
-5.04%
-0.40
Weekly Report: what happened at ABEO last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ABEO last week (0401-0405)?
Weekly Report · 04/08 11:22
ABEONA THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/01 12:30
Weekly Report: what happened at ABEO last week (0325-0329)?
Weekly Report · 04/01 11:19
Weekly Report: what happened at ABEO last week (0318-0322)?
Weekly Report · 03/25 11:22
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's, Q4 earnings came out today. Taysha Gene Therapies shares moved upwards by 29.36%.
Benzinga · 03/19 21:34
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023
Abeona Therapeutics reported earnings per share of -64 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -47 cents. Abeona TherAPEutics is a biotechnology company.
Investorplace · 03/19 10:53
Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility
Abeona Therapeutics shares were down 13% to $7.50. The company said the FDA completed a pre-license inspection of its Cleveland, Ohio, manufacturing facility. The stock hit its 52-week high of $9.01 on March 6. Abeona said the inspection was in relation to its Biologics License Application for pz-cel.
Dow Jones · 03/18 14:24
Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers
Healthcare On the Move: Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers. S&P 500 Health Care Sector +0.1% to 1692.1. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/18 14:00
Abeona Therapeutics GAAP EPS of -$2.53, revenue of $3.5M
Abeona Therapeutics reports FY GAAP EPS of -$2.53, revenue of $3.5M (+146.5% Y/Y) Cash and cash equivalents totaled $52.6 million as of December 31, 2023. The company expects to close out the year with $2.5 million in cash.
Seeking Alpha · 03/18 11:41
Press Release: Abeona Therapeutics Reports Full -2-
ABEONA THERAPEUTICS INC. And its subsidiaries report their consolidated financial results for the years ended December 31, 2013. The company has a net loss of $1.2 billion. The Company has a total debt of $8.1 billion and a total of $7.7 billion.
Dow Jones · 03/18 11:30
Press Release: Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections. FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL(TM) study. Abeona also reported financial results for the full year of 2023.
Dow Jones · 03/18 11:30
Weekly Report: what happened at ABEO last week (0311-0315)?
Weekly Report · 03/18 11:20
Weekly Report: what happened at ABEO last week (0304-0308)?
Weekly Report · 03/11 11:17
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 03/05 06:30
Weekly Report: what happened at ABEO last week (0226-0301)?
Weekly Report · 03/04 11:20
Weekly Report: what happened at ABEO last week (0219-0223)?
Weekly Report · 02/26 11:34
Weekly Report: what happened at ABEO last week (0212-0216)?
Weekly Report · 02/19 11:36
Weekly Report: what happened at ABEO last week (0205-0209)?
Weekly Report · 02/12 11:25
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates confidence or concern around the company's prospects. The Dow Jones index closed higher by around 150 points on Wednesday. Recent notable insider transactions for penny stocks include Abeona Therapeutics and OPKO Health. Processa Pharmaceuticals, Inc. Is one of the companies with recent insider transactions.
Benzinga · 02/08 14:41
More
Webull provides a variety of real-time ABEO stock news. You can receive the latest news about Abeona Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.